23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Enliven Therapeutics, Inc. › 2025-2026

Enliven Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Enliven Therapeutics, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Reported items
  • 189Asset managers, any item
  • 1,638Fund votes
  • June 9, 2026Meeting date

Results at a glance

Meeting of June 9, 2026: 5 items on Enliven Therapeutics, Inc.’s Form 8-K, filed June 10, 2026: 2 elected · 3 approved.

Dissent

Significant dissent: 1 director (35.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2025-2026

Explore Enliven Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Enliven Therapeutics, Inc.

These tallies are Enliven Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Enliven Therapeutics, Inc. — official shareholder meeting results, meeting held June 9, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Richard Fair, M.B.A. 50,534,439---- 152,1885,452,158 99.7%Elected—
Elect Director: Lori Kunkel, M.D. 32,788,330---- 17,898,2975,452,158 65%Elected—
2. Ratification of the Appointment of Independent Registered Public Accounting Firm 56,119,49379518,497 --0 99.9%Approved—
3. Amendment to the Amended and Restated Certificate of Incorporation, as Amended, to Increase the Company's Authorized Shares of Common Stock from 100,000,000 Shares to 200,000,000 Shares 54,711,846373,2151,053,724 --0 99.3%Approved—
4. Approval, in an Advisory (Non-binding) Vote, the Compensation of the Company's Named Executive Officers as Disclosed in the Proxy Statement 47,572,1533,093,44721,027 --5,452,158 94%Approved—

Source: Enliven Therapeutics, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.

How asset managers voted at the Enliven Therapeutics, Inc. 2025-2026 meeting

189 asset managers disclosed a vote on at least one Enliven Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Enliven Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Lori Kunkel, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%WITHHELD
FOR: 32,788,330WITHHELD: 17,898,297
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Lori Kunkel, M.D.

Enliven Therapeutics, Inc.’s own tally for this item (“Elect Director: Lori Kunkel, M.D.”): 32,788,330 for, 17,898,297 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class III Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders or until their successor is duly elected and qualified or until their earlier death, resignation or removal.”
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 8,893,647 for, 3,600,689 withheld, 33 abstained.

FORWITHHOLD
FOR: 8,893,647ABSTAIN: 33WITHHOLD: 3,600,689
Largest asset managers voting on “To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual ” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,139,7590 00For
Vanguard8,9800 332,467,165Withhold
BlackRock1,729,1250 00For
AllianceBernstein00 0409,917Withhold
Charles Schwab361,1170 00For
Dimensional00 0227,320Withhold
Prudential/PGIM137,4390 041,726Mixed
Principal00 092,547Withhold
T. Rowe Price92,0020 00For
Equitable63,4220 024,890Mixed
State Street800 081,423Withhold
QUANTITATIVE MASTER SERIES LLC60,9230 00For
TIAA56,4060 00For
American Century00 054,438Withhold
Tema ETF Trust49,5890 00For
Lincoln Financial00 045,551Withhold
Neuberger Berman39,6320 00For
Advisors' Inner Circle Fund III36,1490 00For
Northern Trust00 024,160Withhold
AIG/SunAmerica00 020,685Withhold
Global X18,6310 00For
AuguStar00 017,488Withhold
ProShares00 015,638Withhold
Advisor Managed Portfolios15,0550 00For
Franklin Alternative Strategies Funds13,7640 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Elect Director: Richard Fair, M.B.A.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 50,534,439WITHHELD: 152,188
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Richard Fair, M.B.A.

Enliven Therapeutics, Inc.’s own tally for this item (“Elect Director: Richard Fair, M.B.A.”): 50,534,439 for, 152,188 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class III Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders or until their successor is duly elected and qualified or until their earlier death, resignation or removal.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 12,476,873 for, 17,497 withheld.

FOR
FOR: 12,476,873WITHHOLD: 17,497
Largest asset managers voting on “To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual ” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,139,7590 00For
Vanguard2,476,1780 00For
BlackRock1,729,1250 00For
AllianceBernstein409,9170 00For
Charles Schwab361,1170 00For
Dimensional227,3200 00For
Prudential/PGIM179,1650 00For
Principal92,5470 00For
T. Rowe Price92,0020 00For
Equitable88,3120 00For
State Street81,4940 09For
QUANTITATIVE MASTER SERIES LLC60,9230 00For
TIAA56,4060 00For
American Century54,4380 00For
Tema ETF Trust49,5890 00For
Lincoln Financial45,5510 00For
Neuberger Berman39,6320 00For
Advisors' Inner Circle Fund III36,1490 00For
Northern Trust24,1600 00For
AIG/SunAmerica20,6850 00For
Global X18,6310 00For
AuguStar00 017,488Withhold
ProShares15,6380 00For
Advisor Managed Portfolios15,0550 00For
Franklin Alternative Strategies Funds13,7640 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Amendment to the Amended and Restated Certificate of Incorporation, as Amended, to Increase the Company's Authorized…

Official resultCAPITAL STRUCTUREReported outcome: Approved

99.3% Approved · of votes cast

FOR 99.3%
FOR: 54,711,846AGAINST: 373,215
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.

Enliven Therapeutics, Inc.’s own tally for this item (“3. Amendment to the Amended and Restated Certificate of Incorporation, as Amended, to Increase the Company's Authorized Shares of Common Stock from 100,000,000 Shares to 200,000,000 Shares”): 54,711,846 for, 373,215 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment to the Amended and Restated Certificate of Incorporation, as amended, to increase the Company's authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 12,460,917 for, 33,449 against, 3 abstained.

FOR
FOR: 12,460,917AGAINST: 33,449ABSTAIN: 3
Largest asset managers voting on “To amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares ” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,139,7590 00For
Vanguard2,472,3093,866 30For
BlackRock1,729,1250 00For
AllianceBernstein409,9170 00For
Charles Schwab361,1170 00For
Dimensional227,3200 00For
Prudential/PGIM167,36511,800 00Mixed
Principal92,5470 00For
T. Rowe Price92,0020 00For
Equitable88,3120 00For
State Street81,47330 00For
QUANTITATIVE MASTER SERIES LLC60,9230 00For
TIAA56,4060 00For
American Century54,4380 00For
Tema ETF Trust49,5890 00For
Lincoln Financial45,5510 00For
Neuberger Berman39,6320 00For
Advisors' Inner Circle Fund III35,883266 00For
Northern Trust24,1600 00For
AIG/SunAmerica20,6850 00For
Global X18,6310 00For
AuguStar017,488 00Against
ProShares15,6380 00For
Advisor Managed Portfolios15,0550 00For
Franklin Alternative Strategies Funds13,7640 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Approval, in an Advisory (Non-binding) Vote, the Compensation of the Company's Named Executive Officers as Disclosed in…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 47,572,153AGAINST: 3,093,447
Details: description as filed, official tally, votes by 189 asset managers

Description as filed by funds: To approve, in an advisory (non- binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.

Enliven Therapeutics, Inc.’s own tally for this item (“4. Approval, in an Advisory (Non-binding) Vote, the Compensation of the Company's Named Executive Officers as Disclosed in the Proxy Statement”): 47,572,153 for, 3,093,447 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, in an advisory (non-binding) vote, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 57 asset managers voting on “To approve, in an advisory (non- binding) vote, the compensation of our named executive officers as disclosed ” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,139,7590 00For
Vanguard2,470,4065,771 00For
BlackRock1,729,1250 00For
AllianceBernstein409,9170 00For
Charles Schwab361,1170 00For
Dimensional0227,320 00Against
Prudential/PGIM166,95412,211 00Mixed
Principal92,5470 00For
T. Rowe Price92,0020 00For
Equitable88,3120 00For
State Street81,48023 00For
QUANTITATIVE MASTER SERIES LLC60,9230 00For
TIAA56,4060 00For
American Century054,438 00Against
Tema ETF Trust49,5890 00For
Lincoln Financial45,5510 00For
Neuberger Berman039,632 00Against
Advisors' Inner Circle Fund III036,149 00Against
Northern Trust024,160 00Against
AIG/SunAmerica20,6850 00For
Global X018,631 00Against
AuguStar00 17,4880Abstain
ProShares15,6380 00For
Advisor Managed Portfolios15,0550 00For
Franklin Alternative Strategies Funds13,7640 00For

Fund voting reports, all 57 managers: 12,022,938 for, 453,944 against, 17,488 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 149 asset managers voting on “To approve, in an advisory (non- binding) vote, the compensation of our named executive officers as disclosed ” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Polar Capital Holdings Plc9,884,3360 00For
ORBIMED ADVISORS LLC7,957,4130 00For
Fidelity5,303,6100 00For
Commodore Capital LP2,410,0000 00For
Vestal Point Capital, LP2,356,3330 00For
Fairmount Funds Management LLC1,855,6440 00For
BlackRock1,401,4375,935 00For
Novo Holdings A/S1,200,0000 00For
Venrock Adviser, LLC1,175,6720 00For
GEODE CAPITAL MANAGEMENT, LLC1,032,5590 00For
Citadel1,010,5290 00For
PICTET ASSET MANAGEMENT SA929,2800 00For
State Street867,9702,157 00For
Rock Springs Capital Management LP808,0950 00For
Siren, L.L.C.746,2260 00For
AllianceBernstein740,3210 00For
Candriam S.C.A.0594,079 00Against
Affinity Asset Advisors, LLC418,5190 00For
Avidity Partners Management LP0400,000 00Against
Charles Schwab366,9560 00For
Vanguard362,1440 00For
First Light Asset Management, LLC343,5590 00For
Woodline Partners LP330,5150 00For
Northern Trust10,675236,624 00Against
ADAR1 Capital Management, LLC240,4600 00For

Institutional-manager reports, all 149 managers: 43,622,487 for, 2,374,113 against, 705 abstained, 11,964 1 year. Showing the 25 largest; every one is in the interactive database (link above).

To approve, in an advisory (non- binding) vote, the frequency of future stockholder advisory votes on the compensation…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.9% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 187 asset managers

Description as filed by funds: To approve, in an advisory (non- binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 57 asset managers voting on “To approve, in an advisory (non- binding) vote, the frequency of future stockholder advisory votes on the comp” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity00 00--
Vanguard00 00--
BlackRock00 00--
AllianceBernstein00 00--
Charles Schwab00 00--
Dimensional00 00--
Prudential/PGIM00 00--
Principal00 00--
T. Rowe Price00 00--
Equitable00 00--
State Street00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
TIAA00 00--
American Century00 00--
Tema ETF Trust00 00--
Lincoln Financial20,1510 00For
Neuberger Berman00 00--
Advisors' Inner Circle Fund III00 00--
Northern Trust00 00--
AIG/SunAmerica00 00--
Global X00 00--
AuguStar00 17,4880Abstain
ProShares00 00--
Advisor Managed Portfolios00 00--
Franklin Alternative Strategies Funds00 00--

Fund voting reports, all 57 managers: 32,653 for, 17,488 abstained, 12,200,897 1 year, 243,238 3 year, 94 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 146 asset managers voting on “To approve, in an advisory (non- binding) vote, the frequency of future stockholder advisory votes on the comp” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Polar Capital Holdings Plc00 00--
ORBIMED ADVISORS LLC00 00--
Fidelity00 00--
Commodore Capital LP00 00--
Vestal Point Capital, LP00 00--
Fairmount Funds Management LLC00 00--
BlackRock00 00--
Novo Holdings A/S00 00--
Venrock Adviser, LLC00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
Citadel00 00--
PICTET ASSET MANAGEMENT SA00 00--
State Street00 00--
Rock Springs Capital Management LP00 00--
Siren, L.L.C.00 00--
AllianceBernstein00 00--
Candriam S.C.A.00 00--
Affinity Asset Advisors, LLC00 00--
Avidity Partners Management LP00 00--
Charles Schwab00 00--
Vanguard00 00--
First Light Asset Management, LLC343,5590 00For
Northern Trust00 00--
ADAR1 Capital Management, LLC00 00--
Logos Global Management LP00 00--

Institutional-manager reports, all 146 managers: 683,501 for, 194 against, 45,049,036 1 year, 70,973 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 56,119,493AGAINST: 795

Prior year: 100.0% for (June 24, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.

Enliven Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 56,119,493 for, 795 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 12,476,882 for, 17,488 abstained.

FOR
FOR: 12,476,882ABSTAIN: 17,488
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for ou” at Enliven Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,139,7590 00For
Vanguard2,476,1780 00For
BlackRock1,729,1250 00For
AllianceBernstein409,9170 00For
Charles Schwab361,1170 00For
Dimensional227,3200 00For
Prudential/PGIM179,1650 00For
Principal92,5470 00For
T. Rowe Price92,0020 00For
Equitable88,3120 00For
State Street81,5030 00For
QUANTITATIVE MASTER SERIES LLC60,9230 00For
TIAA56,4060 00For
American Century54,4380 00For
Tema ETF Trust49,5890 00For
Lincoln Financial45,5510 00For
Neuberger Berman39,6320 00For
Advisors' Inner Circle Fund III36,1490 00For
Northern Trust24,1600 00For
AIG/SunAmerica20,6850 00For
Global X18,6310 00For
AuguStar00 17,4880Abstain
ProShares15,6380 00For
Advisor Managed Portfolios15,0550 00For
Franklin Alternative Strategies Funds13,7640 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Largest Enliven Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,889,655 shares outstanding at the time of that meeting.

Fund voting reports: top Enliven Therapeutics, Inc. shareholders by shares voted on “To approve, in an advisory (non- binding) vote, the compensation of our named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 10.08%
2Vanguard 4.07%
3BlackRock 2.84%
4AllianceBernstein 0.67%
5Charles Schwab 0.59%
6Dimensional 0.37%
7Prudential/PGIM 0.29%
8Principal 0.15%
9T. Rowe Price 0.15%
10Equitable 0.15%
Institutional-manager reports: top Enliven Therapeutics, Inc. shareholders by shares voted on “To approve, in an advisory (non- binding) vote, the compensation of our named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Polar Capital Holdings Plc 16.23%
2ORBIMED ADVISORS LLC 13.07%
3Fidelity 8.71%
4Commodore Capital LP 3.96%
5Vestal Point Capital, LP 3.87%
6Fairmount Funds Management LLC 3.05%
7BlackRock 2.31%
8Novo Holdings A/S 1.97%
9Venrock Adviser, LLC 1.93%
10GEODE CAPITAL MANAGEMENT, LLC 1.70%

Reported Enliven Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Enliven Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with OrbiMed Advisors LLC7,959,538 13.07%Proxy statement (DEF 14A), table as of March 31, 2026
Entities affiliated with FMR LLC7,870,219 12.93%Proxy statement (DEF 14A), table as of March 31, 2026
FMR (Fidelity)6,829,246 11.22%Form 13F, quarter ended March 31, 2026
Polar Capital Holdings Plc5,056,807 8.30%Schedule 13G, filed June 22, 2026
Commodore Capital LP4,800,940 7.88%Schedule 13G, filed May 15, 2026
Fairmount Healthcare Fund II LP3,711,444 6.10%Proxy statement (DEF 14A), table as of March 31, 2026
BlackRock3,684,707 6.05%Form 13F, quarter ended March 31, 2026
Vestal Point Capital, LP3,250,000 5.34%Schedule 13G, filed May 15, 2026
Entities affiliated with Venrock Healthcare Capital Partners3,226,331 5.30%Proxy statement (DEF 14A), table as of March 31, 2026
Vanguard Group2,801,665 4.60%Form 13F, quarter ended March 31, 2026

Percentages above are of 60,889,655 shares outstanding, as reported by Enliven Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Enliven Therapeutics, Inc.'s shareholder meeting held June 9, 2026, in the 2025-2026 proxy season, 189 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,638 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, in an advisory (non- binding) vote, the compensation of our named executive… — Enliven Therapeutics, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Enliven Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Enliven Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Enliven Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Enliven Therapeutics (ELVN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/enliven-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.